DGAP-News: RISE Closes Additional Tranche of Convertible Note Financing

Nachricht vom 04.12.2018 (www.4investors.de) -

DGAP-News: RISE Life Science Corp. / Key word(s): Miscellaneous

RISE Closes Additional Tranche of Convertible Note Financing
04.12.2018 / 20:17

The issuer is solely responsible for the content of this announcement.

Toronto, Ontario--(Newsfile Corp. - December 4, 2018) - RISE Life Science Corp. (CSE: RLSC) (the 'Company' or 'RISE') is pleased to announce that it has completed a second tranche of its offering previously announced on November 14, 2018 (the 'Offering') of unsecured convertible notes (the 'Notes'), raising an additional C$1,490,000. Pursuant to the Offering, the Company has now raised an aggregate of $5,525,000.The Notes will accrue interest at a rate of 12% per year, paid quarterly in cash to the holders of the Notes. The maximum term of the Notes is 24 months. The minimum term of the Notes is twelve months, after which time the Company can repay the principal amount of the Notes and any accrued but unpaid interest without penalty or bonus.At any time prior to repayment of Notes by the Company, the outstanding principal amount of each Note and any accrued and unpaid interest is convertible at the sole discretion of the noteholder into common shares of the Company ('Common Shares') at the conversion price of C$0.15 per share. In addition, Notes are convertible by the Company in its discretion into Common Shares at the conversion price of C$0.15 per share in the event that the Common Shares trade at C$0.35 or more for 21 or more consecutive trading days on the Canadian Securities Exchange.The purchasers of the Notes in this second tranche closing were also issued an aggregate of 9,932,340 Common Share purchase warrants of the Company ('Warrants'), each Warrant exercisable for 24 months from the date of issue for C$0.15 per Warrant, into (i) one Common Share, and (ii) one half of one Common Share purchase warrant (each whole such warrant a 'Bonus Warrant'). Each Bonus Warrant shall be exercisable into one Common Share at an exercise price of C$0.20 per share and shall expire 12 months from the date of its issuance.The proceeds from the Offering will be used to finance the fulfillment of existing and expected orders for RISE's CBD-based products, and for general working capital purposes as the company continues to execute its growth strategy.The Notes were sold pursuant to applicable registration and prospectus exemptions to qualified investors. This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act'), or the securities laws of any state of the United States and may not be offered or sold within the United States (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.About RISE Life Science Corp.RISE is currently developing and evolving medical and adult-use hemp-based formulations to create general use health and well-being products for the emerging consumer category made possible by legal U.S. Farm Bill compliant hemp. The Company launched its CBD-based sexual wellness brand, Karezza in June 2018. The acquisition of Life Bloom Organics in July 2018 expanded RISE's portfolio of CBD products from sexual health and wellness products to include general wellness and sleep products and provides access to Life Bloom's existing channels of distribution and production in the United States and California in particular. RISE also leverages Life Bloom's proprietary process of nanotizing CBD for increased bioavailability (without psychoactivity) in future products created under the RISE brand umbrella. Cautionary Statement Regarding Forward-Looking InformationThe Canadian Securities Exchange has not reviewed this news release and does not accept responsibility for the adequacy or accuracy of this news release.Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in RISE's periodic filings with Canadian securities regulators. When used in this news release, words such as 'will, could, plan, continue, estimate, expect, intend, may, potential, believe, should, target, goals, projections, anticipated' and similar expressions, are forward- looking statements. Forward-looking statements may include, without limitation, statements including the Company's expectations with respect to pursuing new opportunities and its future growth and other statements of fact.Although RISE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: general economic conditions; pending and proposed legislative or regulatory developments including the impact of changes in laws, regulations and the enforcement thereof; reliance on funding models; operational and infrastructure risks including possible equipment failure and performance of information technology systems; intensifying competition resulting from established competitors and new entrants in the businesses in which the Company operates; insurance coverage of sufficient scope to satisfy any liability claims; fluctuations in total customers; technological change and obsolescence; loss of services of key senior management personnel; privacy laws; leverage and restrictive covenants; fluctuations in cash timing and amount of capital expenditures; tax-related risks; unpredictability and volatility of the price of the Company's securities; dilution; and future sales of the Company's securities. Further risks include operational risks of operating in the U.S.; U.S. federal regulation risks; variation in U.S. state regulations; change of U.S. cannabis laws; security risks; risks related to permits and authorizations; risks on liability, enforcement complaints etc.; banking risks; marketing, sales, manufacturing and distribution risk regarding our product growth plans; changes in laws; limited operating history; reliance on management; requirements for additional financing; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult use cannabis industry; and regulatory or political change. There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events. Accordingly, readers should not place undue reliance on forward-looking statements.For Investor inquiries, please contact:Scott Secord, Executive Chairmanssecord@riselifescience.comT. 416.433.9259For Media inquiries, please contact:Jesse Sharratt, Growth Managerjesse@riselifescience.comT. 1.855.477.RISE

Click on, or paste the following link into your web browser, to view
the associated documents


04.12.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

RISE Life Science Corp.


End of News
DGAP News Service

754473  04.12.2018 

Aktuelle Nachrichten aus der 4investors-Redaktion

08.12.2018 - Fresenius setzt sich gegen Akorn durch
08.12.2018 - Elmos Semiconductor: 21 Millionen Euro für Aktienrückkauf
08.12.2018 - BASF: Gewinnwarnung für 2018 - Aktie unter Druck
07.12.2018 - Gerry Weber meldet operativ einen dreistelligen Millionenverlust
07.12.2018 - DCI hält Wort bei der Content Factory 1 GmbH
07.12.2018 - Morphosys: Guselkumab bleibt eine Quelle guter News
07.12.2018 - Black Pearl Digital: Montag ist Stichtag
07.12.2018 - Medigene Aktie: Die Bären in der Falle?
07.12.2018 - Wirecard Aktie: Keine guten Nachrichten - trotz Kursanstieg
07.12.2018 - windeln.de: Entscheidende Tage im Januar


07.12.2018 - Medigene Aktie: Die Bären in der Falle?
07.12.2018 - Wirecard Aktie: Keine guten Nachrichten - trotz Kursanstieg
07.12.2018 - JinkoSolar Aktie: Hier entwickeln sich interessante Dinge!
07.12.2018 - Evotec Aktie erholt sich vom Schock-Tag - neue Phantasie
07.12.2018 - BASF Aktie: Erholung deutet sich an - die Wende?
07.12.2018 - Deutsche Bank Aktie: Hoffnung kommt auf!
07.12.2018 - Commerzbank Aktie: Wo ebbt die Verkaufswelle ab?
06.12.2018 - Paion Aktie: Gelingt die Wende an dieser Chartmarke?
06.12.2018 - Evotec Aktie: Erste Signale der Entspannung, aber…
06.12.2018 - SGL Carbon Aktie: Selloff vorüber, oder was kommt hier noch?


07.12.2018 - Fresenius: Völlige Uneinigkeit bei den Experten
07.12.2018 - Daimler: Achtung - Kursziel liegt unter dem Kurs der Aktie
07.12.2018 - Fresenius: Ein deutliches Kaufvotum für die Aktie
07.12.2018 - ThyssenKrupp: Ein deutliches Minus
07.12.2018 - Fresenius: Analysten bleiben relativ gelassen
07.12.2018 - Fresenius Medical Care: Prognose bringt Kurs unter Druck
07.12.2018 - SAP: Erster Blick auf die Quartalszahlen
07.12.2018 - Leoni: Deutliche Abstufung der Aktie
07.12.2018 - Volkswagen: Positive Entwicklung
06.12.2018 - Hella: Im Wachstumsmodus


07.12.2018 - Spotanalyse USA: Arbeitsmarktbericht für den November - VP Bank Kolumne
07.12.2018 - Forex - EUR/USD: Wieder in der Zwickmühle - UBS Kolumne
07.12.2018 - DAX: Massiver Einbruch belastet schwer - UBS Kolumne
07.12.2018 - Auftragseingänge: Deutliche Erholung gegenüber dem Tiefpunkt im Sommer - Commerzbank Kolumne
07.12.2018 - Deutschland: Industrieproduktion enttäuscht im Oktober - VP Bank Kolumne
07.12.2018 - DAX: Wunden lecken, aber die Entzündung bleibt - Donner & Reuschel Kolumne
06.12.2018 - USA: ISM PMI Non-Manufacturing auf gefährlich hohem Niveau - Nord LB Kolumne
06.12.2018 - Deutschland: Die Krise fällt aus - VP Bank Kolumne
06.12.2018 - EM-Aktien mit Outperformance im November 2018 - neues Votum: Neutral - Commerzbank Kolumne
06.12.2018 - Apple Aktie: Abwärtstrend noch nicht ausgestanden - UBS Kolumne

All Right Reserved by minimalthemes - ©2018 Stoffels & Barck GbR